[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bayer Ag ADR (BAYRY)

Bayer Ag ADR (BAYRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 41,508,660
  • Shares Outstanding, K 3,930,000
  • Annual Sales, $ 51,564 M
  • Annual Income, $ -4,096 M
  • EBIT $ -3,667 M
  • EBITDA $ 1,932 M
  • 60-Month Beta 0.59
  • Price/Sales 0.82
  • Price/Cash Flow 4.84
  • Price/Book 1.22
  • Price/Earnings ttm 7.19
  • Earnings Per Share ttm 1.49
  • Most Recent Earnings $0.79 on 05/12/26
  • Next Earnings Date 08/05/26
  • Annual Dividend & Yield (Fwd) 0.02 (0.22%)
  • Most Recent Dividend 0.024 on 04/28/26
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.23
  • Number of Estimates 2
  • High Estimate $0.26
  • Low Estimate $0.20
  • Prior Year $0.35
  • Growth Rate Est. (year over year) -34.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.5840 +12.79%
on 06/02/26
11.1100 -2.70%
on 06/17/26
-0.3000 (-2.70%)
since 05/22/26
3-Month
9.5840 +12.79%
on 06/02/26
12.2200 -11.54%
on 04/15/26
-0.1600 (-1.46%)
since 03/20/26
52-Week
7.1900 +50.35%
on 08/06/25
14.8500 -27.21%
on 02/17/26
+3.1300 (+40.76%)
since 06/20/25

Most Recent Stories

More News
Bayer and Iambic Collaborate to Advance Drug Discovery with AI

Collaboration focuses on small molecule discovery Bayer to leverage Iambic’s AI platform to address hard-to-drug targets Collaboration will strengthen Bayer’s research...

BAYRY : 10.8100 (+2.35%)
BAYZF : 43.1600 (-2.60%)
BAYN : 0.0100 (unch)
Bayer Welcomes Kacy Perry as New Country Division Head for Crop Science Canada

The Crop Science division of Bayer announced that Kacy Perry has been appointed the Country Division Head (CDH) for Crop Science Canada, effective July 1. In this role, she will lead 550+ employees working...

BAYRY : 10.8100 (+2.35%)
BAYZF : 43.1600 (-2.60%)
BAYN : 0.0100 (unch)
Bayer Completes Acquisition of Perfuse Therapeutics

Bayer today announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully integrated into Bayer. As announced previously ,...

BAYRY : 10.8100 (+2.35%)
BAYZF : 43.1600 (-2.60%)
BAYN : 0.0100 (unch)
Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief

Key Facts Campaign: Project DIY is a new campaign under Aleve’s recently launched Feel Aleve ® platform. Project DIY showcases how, when...

BAYRY : 10.8100 (+2.35%)
BAYZF : 43.1600 (-2.60%)
BAYN : 0.0100 (unch)
Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions

Key Facts: Bayer’s AMBELVIST ® (gadoquatrane) becomes the lowest-dose macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) approved...

BAYRY : 10.8100 (+2.35%)
BAYZF : 43.1600 (-2.60%)
BAYN : 0.0100 (unch)
Dr. Jost Reinhard Appointed President of Bayer’s Radiology Business

Bayer today announced that Dr. Jost Reinhard has been appointed President of the Radiology business within Bayer’s Pharmaceuticals Division, effective August 1, 2026. In his new capacity, he will report...

BAYRY : 10.8100 (+2.35%)
BAYZF : 43.1600 (-2.60%)
BAYN : 0.0100 (unch)
Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth

Bayer today announced leadership changes within its Consumer Health division to accelerate growth, strengthen commercial execution, and further enhance speed of decision making. These changes reflect the...

BAYRY : 10.8100 (+2.35%)
BAYZF : 43.1600 (-2.60%)
BAYN : 0.0100 (unch)
Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease

Investigational results from FIND-CKD provide full efficacy and safety data and is the fifth consecutive Phase III clinical trial where KERENDIA met its primary endpoint—adding to a clinical trial program...

BAYRY : 10.8100 (+2.35%)
BAYZF : 43.1600 (-2.60%)
BAYN : 0.0100 (unch)
Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Presentations also include the INFINITY pooled analysis of KERENDIA ® (finerenone) across diabetic and non-diabetic chronic kidney disease.

BAYRY : 10.8100 (+2.35%)
BAYZF : 43.1600 (-2.60%)
BAYN : 0.0100 (unch)
ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial

Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA ® (darolutamide) showing a decline in maximally changed cognitive domain (MCCD)...

BAYRY : 10.8100 (+2.35%)
BAYZF : 43.1600 (-2.60%)
BAYN : 0.0100 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses....

See More

Key Turning Points

3rd Resistance Point 11.1733
2nd Resistance Point 11.0367
1st Resistance Point 10.9233
Last Price 10.8100
1st Support Level 10.6733
2nd Support Level 10.5367
3rd Support Level 10.4233

See More

52-Week High 14.8500
Fibonacci 61.8% 11.9239
Fibonacci 50% 11.0200
Last Price 10.8100
Fibonacci 38.2% 10.1161
52-Week Low 7.1900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.